Coordinating Care for TGCT: What Can You Bring to the Table?
The goal of this activity is to update clinicians on advances in the management of tenosynovial giant cell tumor (TGCT).
This activity is intended for hematology/oncology specialists, orthopedists and orthopedic surgeons, and pediatricians.
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- Rationale for targeted therapy treatment options in TGCT
- Clinical trial data of pharmacologic therapies used in TGCT
Jean-Yves Blay, MD, PhD
Professor of Medical Oncology at the Université Claude Bernard Lyon 1
Head of the Integrated Research Site of Lyon (LYric) of the French National Cancer Institute
Director of the Network of Reference Centers for Sarcomas in France
Chairman of the French Sarcoma Group
Director of the Institute for Clinical Science
Disclosure: Jean-Yves Blay, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer; Blueprint; Daiichi; Deciphera; MSD; plexxikon; Roche
Received grants for clinical research from: Bayer; Blueprint; Daiichi; Deciphera; MSD; Novartis; plexxikon
Owns stock, stock options, or bonds from: Innate
Mindy Tanzola, PhD
Medical Education Director, Medscape, LLC
Tristin Abair, PhD
Senior Medical Writer, Medscape, LLC
Esther Nyarko, PharmD
Associate Director, Accreditation and Compliance, Medscape, LLC
This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Regeneron
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
- 0.25 MOC
- 0.25 AMA PRA Category 1 Credit™
This course is offered through Medscape. To take this course you will be redirected to Medscape's website. You must have an account with Medscape in order to complete this activity.
MOCINGBIRD continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!